Michael Everson, OD
Corneal and Contact Management · Bryan, TXNPI 1841857562
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,688 of the $5,491 with a category attached, or 85.4%. 18 manufacturers reported payments, led by Alcon at 31.9% of the total.
Across 131 payments — averaging $41.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Biotissue Holdings Inc.$973
- Bausch & Lomb Americas Inc.$615
- Novartis$503
- Rxsight Inc$307
- Johnson & Johnson Vision Care, Inc.$281
- plus $1K from 12 others
What the payments were for
- Consulting fees$2004%
- Speaking & faculty fees$1002%
- Travel & lodging$3536%
- Food & beverage$4,68885%
- Gifts$1513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 32 | $1,752 |
| Biotissue Holdings Inc. | 16 | $973 |
| Bausch & Lomb Americas Inc. | 14 | $615 |
| Novartis | 14 | $503 |
| Rxsight Inc | 7 | $307 |
| Johnson & Johnson Vision Care, Inc. | 10 | $281 |
| Coopervision Inc. | 8 | $185 |
| AbbVie | 7 | $171 |
| Visionary Optics LLC | 1 | $151 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $122 |
| Glaukos Corporation | 4 | $122 |
| Dompe US, Inc. | 4 | $111 |
| Harrow Eye, LLC | 2 | $67 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Amgen | 2 | $35 |
| Lensar, Inc. | 1 | $26 |
| NEW World Medical,inc. | 1 | $18 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,491 in reported general payments places this provider in the 85th percentile of 103 corneal and contact management providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 56 | $72,652 |
| RestasisCyclosporine | 16 | $23,247 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 123 | $5,296 |
| Cyclosporine | 12 | $4,066 |
| Prednisolone Acetate | 152 | $3,926 |
| Bromfenac Sodium | 16 | $2,364 |
| Loteprednol Etabonate | 12 | $1,329 |
| Latanoprost | 30 | $335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $615 | $72,65256 claims |
| AbbVieRestasis | $171 | $23,24716 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $122 | $1,32912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 103 corneal and contact management providers in Texas.
Other corneal and contact management in Bryan
- Maurice WilsonConroe$362K
- Roberto SaenzSan Antonio$171K
- Fariba ParmerGrapevine$26K
- Vissett SunHouston$13K
- Napoleon LoveroHouston$12K
- Sairah MalikHouston$10K
- Darlene JonesPlano$9K
- Heriberto RamosCorpus Christi$9K
- Glenn EllisorKingwood$7K
- Danny MalonePlano$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.